CTOs on the Move

Brii Biosciences

www.briibio.com

 
Brii Biosciences (Brii Bio) is a company committed to serving patients` needs and improving public health in China. Founded in early 2018, the company focuses on accelerating innovation and optimizing access to the latest medicines for Chinese patients. Brii Bio helps global partners drive growth and improve return on investment through better understanding of Chinese healthcare systems and access to the world`s second largest pharmaceutical market. The company`s focus is treatments for chronic illnesses with significant burdens, including infectious diseases, liver and lung diseases, and other illnesses. The company is headquartered in the People`s Republic of China and the United ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.briibio.com
  • One City Center 110 Corcoran Street Office 05-110
    Durham, NC USA 27701
  • Phone: 919.240.5605

Executives

Name Title Contact Details
Eleanor de Groot
 Chief Technology Officer Profile

Funding

Brii Biosciences raised $155M on 03/23/2021

Similar Companies

Vyripharm Enterprises

Vyripharm® is a disruptive biopharmaceutical innovator in personalized medicine. We are challenging the status quo by shifting medical paradigms through the integration of traditional and alternative medicines. Our purpose is to push the boundaries to drive innovation by turning groundbreaking science into cutting edge diagnostics and therapeutics.

Corium International

Corium International is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ibis Biosciences a Division of Abbott

Ibis Biosciences a Division of Abbott is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EnteraTech

EnteraTech is a Hilliard, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CODA Biotherapeutics

CODA Biotherapeutics` revolutionary chemogenetic platform aims to control the activity of cells to treat disease. With chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable `switch` protein. Cells modified with the `switch` can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.